OCS — Oculis Holding AG

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1953530 ·
Last close
$9.06
Market Cap
$503.08M
52W High
$34.47
52W Low
$9.01
ADV30
188,402
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -23,568,000 -9,970,000 250,335,000 61,614,000 30,998,000
Mar 2026 0 — -21,728,000 -28,852,000 243,993,000 64,564,000 47,345,000
Dec 2025 0 — -20,633,000 -23,514,000 235,963,000 81,329,000 39,893,000
Sep 2025 0 — -20,296,000 -16,855,000 167,836,000 46,440,000 37,242,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,678,000
Investing CF
$-34,945,000
Financing CF
$106,690,000
CapEx
$-295,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-413,366,000
Inventory
—
Receivables
$1,576,000
ST Investments
$157,470,000
EBIT TTM
$-94,128,000
Pretax Income TTM
$-94,887,000
Interest Exp TTM
$759,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,173,000
EBITDA
$-85,977,000
Free Cash Flow
$-41,372,752
Enterprise Value
$426,109,600
Total Cash
$228,324,000
Total Debt
$2,543,000
Shares Out
55,527,961
Trailing EPS
$-1.70
Book Value
$4.35
ROE
-43.7%
ROA
-25.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -81,672,000 -98,957,000 235,963,000 39,893,000 196,070,000 -66,304,000
Dec 2024 0 -73,204,000 -85,777,000 120,353,000 46,970,000 73,383,000 -48,919,000
Dec 2023 0 -45,851,000 -88,802,000 114,353,000 20,625,000 93,728,000 -55,037,000
Dec 2022 0 -32,376,000 -38,698,000 37,060,000 135,051,000 -97,991,000 -25,074,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.02

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $9.06 · call volume: 10 · put volume: 30
Expected Move to 2026-10-16: ±$1.80 (19.87%) — implied range $7.26 – $10.86 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CAPR CAPRICOR THERAPEUTICS, INC. $506.39M $8.71 —
DRUG BRIGHT MINDS BIOSCIENCES INC. $506.89M $51.66 —
PBYI PUMA BIOTECHNOLOGY, INC. $506.91M $9.82 —
KMDA KAMADA LTD $497.46M $8.62 —
ARVN ARVINAS, INC. $484.55M $7.51 —

News headlines (Yahoo Finance, 1h cache)

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
2026-09-28 12:35 · Yahoo
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
2026-08-31 13:55 · Yahoo
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
2026-08-24 08:00 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-08-14 20:05 · Yahoo
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
2026-08-10 08:45 · Yahoo
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
2026-08-10 07:30 · Yahoo
Oculis Reports Q2 2026 Financial Results and Provides Company Update
2026-08-06 20:05 · Yahoo
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
2026-07-02 08:00 · Yahoo
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
2026-06-11 08:00 · Yahoo
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
2026-06-09 08:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.